This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global Pharmaceutical Leader Chooses Acsis Enterprise Serialization Management Suite To Achieve E-Pedigree Compliance

MARLTON, N.J., April 9, 2013 /PRNewswire/ -- Acsis Inc., the market leader for Enterprise Serialization solutions, today announced Daiichi Sankyo, Inc. selected the Acsis Serialization Management Suite to comply with FDA e-pedigree mandates and other federal regulations. The turnkey solution includes the Acsis proven serialization management solution with best-of-breed vision and printing equipment from Cognex and Domino. Daiichi Sankyo will install this turnkey solution initially as a pilot at the company's packaging plant in Bethlehem, PA, with Acsis managing all aspects of implementation and support. 

The Acsis serialization solution for Daiichi Sankyo ensures the protection of the company's pharmaceutical supply chain against a variety of issues such as counterfeit, diverted, substandard, adulterated, misbranded and/or expired medications. Acsis' serialization solution includes Line Management, Site Management and Serial Aggregation Management capabilities. Collectively, this suite of solutions will ensure compliance with state and federal laws, including:

  • Automating and managing the application of serialized codes on packaging lines
  • Tracking and controlling all parent-to-child relationships
  • Providing real-time access to real-time and historical posting reports, reconciliation reports and serial number status reports
  • Supporting commissioning, de-commissioning, aggregation and de-aggregated events as required, regardless of component hierarchy

Acsis also will provide seamless, pre-built integration with SAP Auto-ID Infrastructure (AII) and Object Event Repository (OER) to share and track real-time product data throughout the supply chain.

"We are proud to partner with Daiichi Sankyo on this important project," said Neil Thall, Acsis CEO. "The Acsis serialization solution provides pharmaceutical companies with the necessary compliance capabilities to ensure consumer safety, in addition to establishing a foundation for achieving product visibility in the warehouse and across the supply chain."

About Daiichi Sankyo Inc.The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com.

About Acsis Inc.Acsis is the market leader for Enterprise Serialization in the Pharmaceutical, Food & Beverage and Industrial markets. With 30 years of proven experience and industry expertise, Acsis offers the only serialization solution that gives customers complete control to track and trace products throughout the supply chain to meet mandates, gain visibility and improve productivity, while reducing chargebacks and counterfeiting. For more information, visit www.acsisinc.com.

Contact: Renee TruttmanAcsis, Inc. Renee.truttmann@acsisinc.com760-201-6243

SOURCE Acsis Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 +0.12 0.01%
NASDAQ 4,462.9020 +20.2040 0.45%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs